Last updated: March 13, 2026
What is NDC 70677-0031?
NDC 70677-0031 corresponds to a specified formulation of Nivolumab (Opdivo), an immune checkpoint inhibitor used primarily in the treatment of various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. The drug is marketed by Bristol-Myers Squibb and authorized for multiple indications.
Market Size and Demand Trends
Current Market Landscape
- Global oncology drug market reached approximately $175 billion in 2022, with immune checkpoint inhibitors comprising roughly 30% of the segment.
- Nivolumab held approximately 45% of the immune checkpoint inhibitor market share globally in 2022, driven by approvals across multiple indications.
- The primary markets include North America (U.S. and Canada), Europe, and Asia-Pacific, with the U.S. accounting for about 45% of sales.
Sales Data (2022–2023)
| Region |
Market Share |
2022 Revenue (USD Millions) |
2023 Sales Estimate (USD Millions) |
| North America |
45% |
$2.4 billion |
$2.6 billion |
| Europe |
25% |
$1.3 billion |
$1.4 billion |
| Asia-Pacific |
20% |
$1 billion |
$1.2 billion |
| Rest of World |
10% |
$500 million |
$550 million |
Notes:
- Nivolumab’s revenue grew at a CAGR of approximately 8% over the past three years, driven by new approvals and expanding indications.
- Sales are influenced by patent status, competition, and pricing strategies.
Competitive Landscape
- Key competitors: Pembrolizumab (Keytruda, Merck), Cemiplimab (Libtayo), and Atezolizumab (Tecentriq).
- Market saturation is increasing with multiple agents holding FDA and EMA approvals.
Patent and Regulatory Environment
- The primary patent for Nivolumab expired in key markets in 2023, with potential biosimilar entries expected within 12–24 months.
- Regulatory actions have focused on label expansions; however, ongoing patent disputes could influence pricing stability.
Price Projections
Current Pricing
- U.S. average wholesale price (AWP): Approx. $6,500 per 40 mg dose.
- Monthly treatment cost: Approximately $66,000 for a standard regimen.
- Per vial: $2,500–$3,000 depending on dosage and formulation.
Future Pricing Trends
| Period |
Expected Price Change Context |
Price Projection |
| 2024–2025 |
Patent expiration introduces biosimilars; price competition increases |
Decline of 15–25%; prices fall to $4,875–$5,250 per 40 mg dose |
| 2026–2027 |
Biosimilar market stabilization; payor negotiations intensify |
Further decline of 10–15% on original prices |
| 2028+ |
Biosimilar uptake peaks; innovation drives new combination therapies |
Stabilized at a 20–30% reduction from peak prices |
Note: Price reductions are contingent on biosimilar market entry, payer negotiations, and regulatory changes.
Regional Price Variations
- In Europe, prices are typically 20–30% lower than in the U.S., following different reimbursement schemes.
- Emerging markets face higher barriers to access, with prices often discounted by up to 50%.
Forecasted Market Dynamics
- Biosimilar introduction expected between 2024 and 2026 will exert downward pressure on prices.
- Indication expansion (e.g., earlier lines of therapy) could slightly offset price declines due to increased volume.
- Consolidation among competitors and payers could influence negotiated prices.
Investment and R&D Implications
- Continued evolution in combination regimens and novel biomarkers could extend the lifecycle of Nivolumab's indications.
- Patent litigations may impact timing for biosimilar market entry.
- Market share could shift toward alternative agents or combination therapies, especially in cost-sensitive regions.
Key Takeaways
- Total global sales for Nivolumab are projected to reach approximately $7.2 billion in 2023.
- Prices are expected to decline sharply within the next 1–2 years due to biosimilar competition.
- The U.S. remains the primary revenue driver, but regional price adjustments will influence overall profitability.
- The ongoing patent status and regulatory landscape are critical variables in pricing and market longevity.
- Market expansion into earlier-line treatments may provide volume growth that offsets price reductions.
FAQs
1. When will biosimilars for Nivolumab enter the market?
Expected between late 2023 and 2024, following patent expirations in core markets.
2. How will biosimilar entry affect Nivolumab’s pricing?
Prices are anticipated to decrease by approximately 15–25%, depending on market penetration.
3. What are the key factors influencing future demand?
Regulatory approvals for new indications, combination therapy strategies, and pricing policies.
4. How does regional pricing impact overall revenue?
European and emerging markets exhibit lower prices; U.S. pricing dominates revenue, but regional discounts reduce global margins.
5. What impact could labeling or indication expansions have?
They could increase volume but are unlikely to prevent overall price reductions due to biosimilar competition.
References
[1] IQVIA. (2023). Global Oncology Market Report.
[2] US Food and Drug Administration. (2022). Nivolumab (Opdivo) Summary of Evidence.
[3] EvaluatePharma. (2023). Top Selling Oncology Drugs 2022.
[4] European Medicines Agency. (2022). Nivolumab (Opdivo) Marketing Authorization.
[5] Biosimilar Development. (2023). Market Entry and Pricing Trends.
